1. Reconciled Endocrinology, Obesity, and Metabolic Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 2,382 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 857 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 1,032 / 219 | 17.51% closed-trial attrition ratio across 1,251 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 40 / 25 / 10 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 86.3% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Endocrinology, Obesity, and Metabolic
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Eli Lilly and Company | Biopharma Industry | 334 | 146 | 156 | 88 |
| Novo Nordisk | Biopharma Industry | 176 | 60 | 104 | 20 |
| Boehringer Ingelheim | Biopharma Industry | 139 | 45 | 70 | 54 |
| Fujian Shengdi Pharmaceutical Co | Biopharma Industry | 37 | 21 | 13 | 0 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Federal / Public Agency | 28 | 17 | 4 | 0 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co | Biopharma Industry | 24 | 16 | 6 | 0 |
| Jaeb Center for Health Research | Academic / Institutional Sponsor | 21 | 11 | 6 | 0 |
| University of Guadalajara | Academic / Institutional Sponsor | 19 | 4 | 7 | 0 |
| Gan & Lee Pharmaceuticals | Biopharma Industry | 15 | 15 | 0 | 0 |
| Medical University of Warsaw | Academic / Institutional Sponsor | 15 | 4 | 4 | 0 |
| Rhythm Pharmaceuticals | Biopharma Industry | 15 | 5 | 10 | 0 |
3. Representative Multi-Center Phase II & III Endocrinology, Obesity, and Metabolic Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07515079 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Bio-Thera Solutions | Phase III | RECRUITING |
| NCT07303803 | A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus | Shanghai Jiao Tong University School of Medicine | Phase II | RECRUITING |
| NCT07088068 | A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Sanofi | Phase III | RECRUITING |
| NCT06962098 | Efficacy and Safety Study of Isuzinaxib in Subjects With DKD | Aptabio Therapeutics | Phase II | RECRUITING |
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes | Vertex Pharmaceuticals | Phase III | RECRUITING |
| NCT07589608 | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight | Eli Lilly and Company | Phase II | RECRUITING |
| NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Madrigal Pharmaceuticals | Phase II | RECRUITING |
| NCT06143956 | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Eli Lilly and Company | Phase II | RECRUITING |
| NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Pfizer | Phase III | RECRUITING |
| NCT06672939 | A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Eli Lilly and Company | Phase III | RECRUITING |
| NCT06672549 | A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Eli Lilly and Company | Phase III | RECRUITING |
| NCT07340320 | A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus | Corxel Pharmaceuticals | Phase II | RECRUITING |
| NCT03633708 | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | Amgen | Phase III | RECRUITING |
| NCT06739122 | A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Eli Lilly and Company | Phase III | RECRUITING |
| NCT07670416 | A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes | Roche / Genentech | Phase III | RECRUITING |
| NCT07296484 | Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Sparrow Pharmaceuticals | Phase II | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.